Navigation Links
Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
Date:9/24/2008

Opening Ceremony Launches Effort to Transform Korean Pharmaceutical Industry

CHUNCHEON CITY, Korea, Sept. 24 /PRNewswire-USNewswire/ --

Civic and business officials gathered in Chuncheon City Sept. 23 to open a worldwide bioequivalence research institute operated by International Scientific Standard, Inc. (ISS), a joint venture company.

ISS, formed by Battelle and YuYu Pharma, will focus on testing the safety and efficacy of generic drugs in order to position the Korean pharmaceutical market for global sales. The ISS pledges to work closely with customers to ensure testing meets global standards.

Bioequivalence testing services begin in the fall in the GLP-compliant laboratory, which will begin operation with 10 to 20 researchers. They'll conduct the work in a 1,090-square meter facility in Chuncheon City that is equipped with state-of-the-art LC/MS equipment imported from Japan and the United States.

The opening ceremony was attended by: Kim Jin Son, Kang Won Provincial Governor; Lee Kwang Jun, Chuncheon Mayor; Dr. Carl Kohrt, Battelle President and CEO; and Dr. Seungpil Yu, Chairman of YuYu Pharma.

Officers of ISS include YuYu Pharma's Dr. Seungpil Yu, who is Chairman of the Board, and Battelle's Dr. Joan Adams, who is Representative Director.

Chuncheon City offered incentives in order to bring the ISS facility to the city because it has the potential to have a positive impact on the economy. Chuncheon estimates new drug development production could eventually reach $168 million annually and potentially create 3,000 jobs.

YuYu Inc. is a pharmaceutical company listed on the Korea Stock Exchange.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. Battelle oversees $
'/>"/>

SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Zephyr(R) EBV Technology Enables Pulmonx to Develop Both ... ALTO, Calif., May 13 Pulmonx, a medical ... with emphysema, announced today that it has acquired ... its endobronchial valve (EBV) technology platform and associated ...
... Technologies Limited (ASX: TEO), a global healthcare company, ... catheter it is developing with Vascular Pathways, Inc., ... Award. , "Telesso is pleased to receive another ... may revolutionize peripheral IV placement," said Telesso,s CEO ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ... Bank 34th Annual Health Care Conference in Boston, Massachusetts, on ... of the presentation can be accessed via Zimmer,s Investor Relations ... The webcast will be archived for replay following the conference. ...
... that it has enrolled its 1,000th patient into its ... esponsiveness with A V erifyNow(R) Assay I ... S afety). The trial is specifically designed to demonstrate ... patients who are poor responders to clopidogrel (Plavix(R)). The ...
... ESRX ) announced that it will present at ... 19, 2009 at 10:10 a.m. EDT at the InterContinental Hotel ... Internet and can be accessed on the investor relations section ... RealPlayer or Windows Media Player is needed to listen to ...
... reduced in rodent models of liver injury, leading ... two factors that contribute to endothelial dysfunction and ... the analysis of the human Cystathionase gene promoter ... Administration of an FXR ligand to carbon tetrachloride ...
Cached Medicine News:Health News:Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting 2Health News:Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting 3Health News:Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial 2Health News:Farnesoid X receptor regulates cystathionase 2
(Date:10/17/2014)... 2014 The following is being released ... The Green Park Collaborative (GPC) will bring ... payers, medical device and pharmaceutical companies, as well ... 12, 2015 at its first ever workshop on ... treatments.  Participants will discuss study designs to evaluate ...
(Date:10/17/2014)...  UBM Medica US announces that Endocrinology Network ... clinicians who treat patients with type 2 diabetes ... of insulin .  Nearly all patients ... – daily injections of one or more insulin ... function of pancreatic beta cells. Insulin is a very ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Visica 2(TM) Treatment System Selected as Exclusive Cryoablation ... ... The American College of,Surgeons Oncology Group (ACOSOG) which just ... Phase II Trial Exploring,the Success of Cryoablation Therapy in the ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Cached Medicine Technology:NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: